Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical University, Midorigaoka E 2-1-1-1, Asahikawa 078-8510, Japan.
Int J Oncol. 2011 May;38(5):1219-26. doi: 10.3892/ijo.2011.949. Epub 2011 Feb 22.
B7-H3 is a member of the B7 family thought to be a co-regulatory factor of antigen-specific T-cell immune response via co-stimulatory and co-inhibitory receptors. We evaluated its potential expression in head and squamous cell carcinoma (SCC) cell lines, and in clinical tissue samples obtained from 37 patients with human hypopharyngeal SCC. All head and neck SCC cell lines tested expressed both the B7-H3 gene and cell surface protein. The staining intensity of immunoreactivity by tumor cells was blindly evaluated by two head and neck surgeons and the results were categorized into 4 grades according to staining intensity. Eighty-seven percent of patients expressed B7-H3. B7-H3 expression was inversely correlated with the number of tumor infiltrating CD8+ T-cells (r=-0.4339, p=0.023). Patients who developed distant metastasis after tumor-free periods showed significantly higher B7-H3 expression scores compared to patients who did not develop distant metastasis during follow-up periods (p=0.048). Distant metastasis control ratio in patients with strong B7-H3 expression was significantly lower compared to that in patients with no to intermediate B7-H3 expression (p=0.040). Cause-specific survival ratio in patients with strong B7-H3 expression was significantly lower compared to that in patients with no to intermediate B7-H3 expression (p=0.028). Moreover, multivariate analysis revealed that strong B7-H3 expression was an independent prognostic factor in tumor-specific death in hypopharyngeal SCC (hazard ratio: 9.803, confidence interval: 0.018-0.539, p=0.0110).
B7-H3 是 B7 家族的一员,被认为是通过共刺激和共抑制受体调节抗原特异性 T 细胞免疫反应的协同调节因子。我们评估了其在头颈部鳞状细胞癌(SCC)细胞系和 37 例人类下咽 SCC 患者临床组织样本中的潜在表达。所有测试的头颈部 SCC 细胞系均表达 B7-H3 基因和细胞表面蛋白。两名头颈外科医生对肿瘤细胞免疫反应的染色强度进行了盲法评估,并根据染色强度将结果分为 4 个等级。87%的患者表达 B7-H3。B7-H3 的表达与肿瘤浸润性 CD8+T 细胞的数量呈负相关(r=-0.4339,p=0.023)。在无肿瘤间期后发生远处转移的患者与在随访期间未发生远处转移的患者相比,B7-H3 表达评分显著更高(p=0.048)。B7-H3 表达较强的患者的远处转移控制率明显低于 B7-H3 表达无到中等的患者(p=0.040)。B7-H3 表达较强的患者的无病生存比明显低于 B7-H3 表达无到中等的患者(p=0.028)。此外,多变量分析显示,B7-H3 表达较强是下咽 SCC 肿瘤特异性死亡的独立预后因素(危险比:9.803,置信区间:0.018-0.539,p=0.0110)。